Kennedy believes that vaccines cause autism and wants to use his perch to carry out further testing.

It's not just vaccine makers that are down following the announcement that former President Donald Trump has nominated Robert ...

Currently, only 21% of Wall Street analysts have Palantir ranked a "buy". This makes Palantir the lowest recommended, best ...

Fintel reports that on November 14, 2024, Citigroup initiated coverage of Amgen (NasdaqGS:AMGN) with a Neutral recommendation ...

Wolfe Research analyst Alexandria Hammond initiated coverage of Amgen (AMGN) with a Peer Perform rating. With the antibody backbone, the firm ...

Analysts have set 12-month price targets for Amgen, revealing an average target of $349.0, a high estimate of $405.00, and a ...

Shares of pharmaceutical giant Amgen (AMGN) are attempting to bounce back after suffering a steep drop of 7.1% yesterday.

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Amgen (AMGN – Research Report), with a price target of $383.00. The company’s shares closed yesterday at $298.84.

As an aside, in the tech space, see What’s Happening With Snap Stock? Although the recent Amgen update didn’t bode well with ...

Amgen (AMGN) stock spiked after the company ruled out out bone density concerns linked to obesity drug MariTide, following a ...